Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

CCK-B/Gastrin Receptor Transmembrane Domain Mutations Selectively Alter Synthetic Agonist Efficacy without Affecting the Activity of Endogenous Peptides

Michael Bläker, Yong Ren, Lakshmi Seshadri, Edward W. McBride, Martin Beinborn and Alan S. Kopin
Molecular Pharmacology August 2000, 58 (2) 399-406; DOI: https://doi.org/10.1124/mol.58.2.399
Michael Bläker
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yong Ren
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakshmi Seshadri
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward W. McBride
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Beinborn
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan S. Kopin
Department of Medicine and the GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Recent efforts have focused on identifying small nonpeptide molecules that can mimic the activity of endogenous peptide hormones. Understanding the molecular basis of ligand-induced receptor activation by these divergent classes of ligands should expedite the process of drug development. Using the cholecystokinin-B/gastrin receptor (CCK-BR) as a model system, we have recently shown that both affinity and efficacy of nonpeptide ligands are markedly affected by amino acid alterations within a putative transmembrane domain (TMD) ligand pocket. In this report, we examine whether residues projecting into the TMD pocket determine the pharmacologic properties of structurally diverse CCK-BR ligands, including peptides and synthetic peptide-derived partial agonists (peptoids). Nineteen mutant human CCK-BRs, each including a single TMD amino acid substitution, were transiently expressed in COS-7 cells and characterized. Binding affinities as well as ligand-induced inositol phosphate production at the mutant CCK-BRs were assessed for peptides (CCK-8 and CCK-4) and for peptoids (PD-135,158 and PD-136,450). Distinct as well as overlapping determinants of peptide and peptoid binding affinity were identified, supporting that both classes of ligands, at least in part, interact with the CCK-BR TMD ligand pocket. Eight point mutations resulted in marked increases or decreases in the functional activity of the synthetic peptoid ligands. In contrast, the functional activity of both peptides, CCK-8 and CCK-4, was not affected by any of the CCK-BR mutations. These findings suggest that the mechanisms underlying activation of G-protein-coupled receptors by endogenous peptide hormones versus synthetic ligands may markedly differ.

Footnotes

    • Received December 7, 1999.
    • Accepted May 9, 2000.
  • Send reprint requests to: Alan S. Kopin, M.D., Department of Medicine and GRASP Digestive Disease Center, New England Medical Center, Box 239, 750 Washington St., Boston, MA 02111. E-mail:akopin{at}lifespan.org

  • ↵1 Equal contributions were made by both authors.

  • ↵2 Present address: Medizinische Kernklinik und Poliklinik, Universitäts-Krankenhaus Eppendorf, 20246 Hamburg, Germany.

  • This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grant DK46767 and an American Gastroenterological Association Industry Research Scholar Award (to M. Beinborn). A.K. is a New England Medical Center Molecular Cardiology Research Institute investigator. M. Bläker is supported by the Deutsche Forschungsgemeinschaft.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 58 (2)
Molecular Pharmacology
Vol. 58, Issue 2
1 Aug 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CCK-B/Gastrin Receptor Transmembrane Domain Mutations Selectively Alter Synthetic Agonist Efficacy without Affecting the Activity of Endogenous Peptides
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

CCK-B/Gastrin Receptor Transmembrane Domain Mutations Selectively Alter Synthetic Agonist Efficacy without Affecting the Activity of Endogenous Peptides

Michael Bläker, Yong Ren, Lakshmi Seshadri, Edward W. McBride, Martin Beinborn and Alan S. Kopin
Molecular Pharmacology August 1, 2000, 58 (2) 399-406; DOI: https://doi.org/10.1124/mol.58.2.399

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

CCK-B/Gastrin Receptor Transmembrane Domain Mutations Selectively Alter Synthetic Agonist Efficacy without Affecting the Activity of Endogenous Peptides

Michael Bläker, Yong Ren, Lakshmi Seshadri, Edward W. McBride, Martin Beinborn and Alan S. Kopin
Molecular Pharmacology August 1, 2000, 58 (2) 399-406; DOI: https://doi.org/10.1124/mol.58.2.399
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of Celecoxib targets by label-free TPP
  • Editing TOP2α Intron 19 5′ SS Circumvents Drug Resistance
  • CTS Bias
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics